(A) Western blot analysis of cell lines treated for 24 hours with the indicated dose and probed for readout of Plk1 inhibition (n=3). (B) EdU incorporation of cells treated with Plk1 inhibitor (GSK461364; 50 nM) for 72 hours, **p<0.01 (n=3). (C) Slopes of the proportion of dead cells after 72 hours of treatment with indicated doses of GSK461364, ***p<0.001. (D) Western blot analysis of pERK½, p-H2AX, MCL-1, BCL-XL, Bak, cleaved PARP, and cleaved-caspase 3 after treatment with Plk1 inhibitor (GSK461364, n=3). (E) Immunofluorescent staining of p-H2AX in CRT14 after treatment with 20 nM GSK461364, *p<0.05 (n=3). (F) Tumor growth, indicated by change in volume over time, of CRT 13 tumors treated with Plk1 inhibitor (GSK461364; 25 mg/kg/dose) in nude mice. (G) Kaplan Meier survival curve of F, ***p<0.001.